A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 In Asian Subjects With Moderate To Severe Chronic Plaque Psoriasis
Phase of Trial: Phase III
Latest Information Update: 03 Sep 2015
At a glance
- Drugs Tofacitinib (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 31 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 30 Jul 2015 Planned primary completion date changed from 1 Nov 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov record.
- 28 Oct 2014 Planned primary completion date changed from 1 Aug 2015 to 1 Nov 2014 as reported by ClinicalTrials.gov record.